GLP-1(28-36)amide, a Long Ignored Peptide Revisited
- Open Biochem J. 2014 Dec 31;8:107-11. doi: 10.2174/1874091X01408010107.
- 1. Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China, 430030.
- 2. Department of Pharmacy, The Third Hospital of Wuhan, Wuhan, Hubei, P. R. China, 430060.
- 3. Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China, 430030 ; Centre for Biomedicine Research, Wuhan Institute of Biotechnology, Wuhan, Hubei, P. R. China, 430075.
Glucagon-like peptide-1 (GLP-1), which has been extensively applied for treating type 2 diabetes mellitus (T2DM), is an incretin hormone that regulates glucose homeostasis. GLP-1(28-36)amide, a C-terminal nonapeptide (FIAWLVKGRamide) of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide has long been regarded as a metabolically inactive byproduct, however, recent findings reveal that GLP-1(28-36)amide plays multiple novel roles in ameliorating hepatic metabolism, protecting β cells, improving glucose disposal and inhibiting weight gain. Here, we summarize the latest progress on the effects of GLP-1(28-36)amide with a focus on its roles in regulating the Wnt and mitochondrial-mediated signaling pathways.